You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Wideband Tunable Multiferroic Electronics for Advanced RF Systems (1000-277)

    SBC: SI2 TECHNOLOGIES, INC.            Topic: ST13B003

    SI2 Technologies proposes to design, model, fabricate and transition wideband tunable multiferroic electronics for advanced RF systems including adaptive Radar, software defined radios and other electronic warfare (EW) applications. Combining novel nanost

    STTR Phase I 2014 Department of DefenseDefense Advanced Research Projects Agency
  2. Multiferroic Materials for RF Applications

    SBC: Winchester Technologies, LLC            Topic: ST13B003

    Voltage tunable multiferroic materials with strong magnetoelectric coupling provide a unique approach to compact, lightweight and power efficient tunable RF/microwave multiferroic components, such as tunable inductors, filters, phase shifters, etc. The tu

    STTR Phase I 2014 Department of DefenseDefense Advanced Research Projects Agency
  3. New heterocyclic inhibitors of filoviruses

    SBC: MICROBIOTIX, INC.            Topic: H

    DESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. New small molecule inhibitors of arenaviruses

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government